Cargando…
Drug repositioning in pulmonary arterial hypertension: challenges and opportunities
Despite many advances in medical therapy for pulmonary arterial hypertension (PAH) over the past 20 years, long-term survival is still poor. Novel therapies which target the underlying pathology of PAH and which could be added to current vasodilatory therapies to halt disease progression and potenti...
Autores principales: | Grinnan, Daniel, Trankle, Cory, Andruska, Adam, Bloom, Bruce, Spiekerkoetter, Edda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852366/ https://www.ncbi.nlm.nih.gov/pubmed/30729869 http://dx.doi.org/10.1177/2045894019832226 |
Ejemplares similares
-
Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension
por: Andruska, Adam, et al.
Publicado: (2018) -
Targeting BMPR2 Trafficking with Chaperones: An Important Step toward Precision Medicine in Pulmonary Arterial Hypertension
por: Andruska, Adam, et al.
Publicado: (2020) -
Repurposing of medications for pulmonary arterial hypertension
por: Toshner, Mark, et al.
Publicado: (2020) -
Role of Long Non-Coding RNAs in Pulmonary Arterial Hypertension
por: Han, Yun, et al.
Publicado: (2021) -
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva
por: Ventura, Francesc, et al.
Publicado: (2021)